Evidence map›Paper›PMID 28687991›Full record

Trial reportInternational journal of hematology2017

Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan.

Akio Saito, Atsushi Isoda, Masaru Kojima, Akihiko Yokohama, Yutaka Tsukune, Makoto Sasaki, Shigeki Ito, Akihiro Ohtsu, Michiaki Koike, Kayoko Murayama and 12 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Akio SaitoDepartment of Hematology, Fujioka General Hospital, Gunma, Japan.
Atsushi IsodaDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma Prefecture, 377-0280, Japan. aisoda@sbmc.hosp.go.jp.ORCID http://orcid.org/0000-0002-3080-2341
Masaru KojimaDepartment of Diagnostic Pathology, Dokkyo University School of Medicine, Tochigi, Japan.
Akihiko YokohamaBlood Transfusion Service, Gunma University Hospital, Gunma, Japan.
Yutaka TsukuneDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Makoto SasakiDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Shigeki ItoDepartment of Medical Oncology, Iwate Medical University School of Medicine, Iwate, Japan.
Akihiro OhtsuDepartment of Medical Oncology, Iwate Medical University School of Medicine, Iwate, Japan.
Michiaki KoikeDepartment of Hematology, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
Kayoko MurayamaDepartment of Hematology, Gunma Cancer Center, Gunma, Japan.
Keiichi MoriyaDivision of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan.
Hideto TamuraDivision of Hematology, Department of Medicine, Nippon Medical School, Tokyo, Japan.
Morio MatsumotoDepartment of Hematology, National Hospital Organization Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma Prefecture, 377-0280, Japan.
Hirotaka NakahashiDepartment of Hematology, Fukaya Red Cross Hospital, Saitama, Japan.
Sakae TanosakiDepartment of Hematology, the Fraternity Memorial Hospital, Tokyo, Japan.
Tohru SakuraLeukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan.
Toshihide KawamuraDepartment of Internal Medicine, Usui Public Hospital, Gunma, Japan.
Tomomi MiyanagaDepartment of Pathology, National Hospital Organization Takasaki General Medical Center, Gunma, Japan.
Naoya NakamuraDepartment of Pathology, School of Medicine, Tokai University, Kanagawa, Japan.
Hirokazu MurakamiDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Hiroshi HandaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Norifumi TsukamotoOncology Center, Gunma University Hospital, Gunma, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although population-based cancer registries have reported lower incidence of Waldenstrӧm macroglobulinemia (WM) in East Asia than in Western countries, previous retrospective analyses have found the clinical features of WM to be similar in these two populations. To clarify the characteristics of Japanese WM patients, we retrospectively analyzed clinical and laboratory characteristics, treatments, outcomes, and prognostic factors in 93 patients with WM. Based on the Second International Workshop on WM (IWWM-2) criteria, symptomatic WM was found in 73 (78.5%) and asymptomatic WM in 20 (21.5%) of cases examined. The median overall survival (OS) was similar to that in reports from Western countries. Patients receiving treatment regimens including rituximab exhibited significantly better survival than those not given rituximab. Although prognostic factors for WM in Western countries may not apply to Japanese patients, our finding that newly diagnosed WM patients with pleural effusion have a poorer prognosis suggests that this may be a novel predictor of adverse prognosis in symptomatic WM.

Indexed as

AdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansJapanMaleMiddle AgedRetrospective StudiesRituximabSurvival RateWaldenstrom MacroglobulinemiaRituximabJapanPleural effusionPrognostic factorRituximabWaldenstrӧm macroglobulinemia

Identifiers

PMID28687991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.